Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms
Sponsor: Kimera Labs Inc.
Summary
Investigational New Drug trial investigating safety as primary endpoint and clinical efficacy as secondary endpoint of placental, mesenchymal stem cell-derived extracellular vesicles for the treatment of COVID-19 symptoms in adults with mild to moderate illness.
Official title: A Stratified Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase I/IIa Clinical Trial to Assess the Safety and Efficacy of a Single Intravenous Dose of Isolated, Placental, Mesenchymal Stem Cell-derived Extracellular Vesicles for the Treatment of COVID-19 Symptoms in Adults With Mild to Moderate Illness
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2027-01
Completion Date
2028-12
Last Updated
2026-06-24
Healthy Volunteers
No
Conditions
Interventions
IV infusion using an isolated, placental, mesenchymal stem cell derived EVs
Single IV infusion of the drug product XoGlo Pro
Placebo IV administration
Placebo IV infusion of normal saline